Brigham doc loses hard drive with info on 638 patients

An external hard drive belonging to a Brigham and Women’s/Faulkner Hospital physician was lost on June 21, potentially affecting 638 patients.

The Boston-based hospital stated in a release that it has notified the potentially-affected patients that their medical information may have been on the device.

The following information related to inpatient hospital stays from July 10, 2009 to January 28, may have been present on the device: patient name, medical record number, dates of admission, medications and information about diagnosis and treatment.

The information did not contain social security numbers, insurance numbers or other financial account information, the organization stressed.

“Brigham and Women’s/Faulkner Hospital takes the privacy and security of our patients’ information very seriously. We are taking steps to reduce the risk of such events occurring in the future, including addressing the incident specifically with those involved, reviewing and augmenting our policies and procedures and enhancing our training regarding technical safeguards required on external hard drives that may contain sensitive data, as well as limiting the amount of data stored on such devices,” said Sue Schade, Brigham and Women’s/Faulkner Hospital’s chief information officer.

As of press time, the hospital stated it has no knowledge that the information on this device has been accessed. As a precaution, it is offering affected patients identity protection services.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.